Supplementary Figure 4 from Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Key Points

• Genomic alterations in patients were identified using plasma and tumor tissue samples, which adds to the understanding of mutation detection.
• Patients receiving taselisib with PIK3CA mutations showed varying treatment responses, depicted by response stratification.
• The analysis involved comparing the presence of mutations in both tissue and plasma, offering insights into the mutations’ distribution.
• Findings highlight the importance of accurate mutation detection in guiding treatment decisions for patients involved in the trial.